Skip to main content
Premium Trial:

Request an Annual Quote

EpiVax, BioAtla Collaborate on Antibody Screening Technology

NEW YORK (GenomeWeb News) – EpiVax's immunogenicity screening technology will be incorporated into BioAtla's antibody Express Humanization platform under a collaboration announced today.

Providence, RI-based EpiVax has developed in silico tools for the immunogenicity screening of protein therapeutics, immunogenicity mitigation, and T cell-driven vaccine design, while San Diego-based BioAtla's Express Humanization platform "entails synthesizing a combinatorial library of non-human target monoclonal antibodies fused in frame to a validated collection of human frameworks, and screening for binding, function, and expression."

Combining the two companies' technologies, they said, provides a third level clone selection criterion for developing human antibody therapeutics, immunogenicity, thereby expanding the functional selectivity of BioAtla's expression-based humanization process.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.